Explore the Effect of Gynostemma Pentaphyllum on Patients With Metabolic Syndrome
Status:
Not yet recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Previous research shows that gypenoside could keep blood lipid and blood sugar under control
in an effective way. In this study, we intend to explore whether gypenosides have clinical
improvement effects on metabolic diseases such as diabetes, hyperlipidemia, and non-alcoholic
fatty liver and their cardiovascular protective potential. It is designed to recruit 150
patients with metabolic syndrome diagnosed who meet the criteria for enrollment, and randomly
divide them into three groups. Gynostemma powder, with two different saponins content (12%
and 8%) from Pingli County, Shaanxi Province, and spinach powder with almost no saponins were
used to conduct the intervention on patients. Patients will be followed up regularly at the
beginning of each month from the first enrollment until the third month. At each follow-up,
data of patient's anthropometric indicators as well as clinical inspection indicators related
to metabolism (blood routine, liver function, etc.) will be recorded. In addition, patient's
blood, hair, urine, and stool samples will be collected to further explore the mechanism of
diseases.
Phase:
N/A
Details
Lead Sponsor:
First Affiliated Hospital Xi'an Jiaotong University